Atorvia is a pre-clinical stage biopharmaceutical company on a mission to transform outcomes for patients with cardio-renal disease. Commercially-minded and patient-centric, we are on a journey to advance and deliver transformative therapies for patients that regulators will approve, payors will pay and providers will adopt. With a lead program focused on ischemia-induced organ failure, initially targeting the kidney, Atorvia has a therapeutic in development for Acute Kidney Injury. This common and often fatal condition leaves surviving patients with cardio-renal diseases and can lead to stroke, myocardial infarction, chronic kidney disease or end stage renal disease. There is currently no treatment available. Headquartered in Massachusetts, USA, with operations in Ontario, Canada, Atorvia is curating a pipeline of technologies that will disrupt the existing landscape and transform outcomes for patients with cardio-renal disease.